A 48-year-old Indian woman with a 10-year history of type 2 diabetes mellitus presents with progressive velvety darkening of her neck, axillae, and inframammary folds over the past 2 years. She denies weight loss and reports stable weight around 78 kg (BMI 32 kg/m²). Her HbA1c is 7.8%, and fasting insulin is 24 mIU/mL (normal: 2–12 mIU/mL). Skin biopsy shows acanthosis with papillomatosis and mild hyperkeratosis. Which of the following is the MOST appropriate next step in management?

Explanation

## Insulin-Resistant Acanthosis Nigricans: Diagnosis & Management ### Clinical Context: Benign vs. Malignant AN **Key Point:** This patient has **insulin-resistant acanthosis nigricans (IRAAN)**, the benign, metabolic form of AN. The clinical features that support this diagnosis are: | Feature | This Patient | IRAAN Pattern | MAAN Pattern | |---------|--------------|---------------|---------------| | **Duration** | 2 years (gradual) | Months to years | Weeks to months | | **Weight status** | Obese (BMI 32) | Usually obese | Often weight loss | | **Systemic symptoms** | None reported | Absent | Weight loss, constitutional | | **Fasting insulin** | 24 mIU/mL (elevated) | Markedly elevated | Normal to low | | **Underlying condition** | Type 2 DM | DM, PCOS, obesity | Occult malignancy | | **Prognosis** | Benign | Benign | Poor (depends on cancer) | **High-Yield:** The **markedly elevated fasting insulin (24 mIU/mL) with stable weight and no constitutional symptoms** is pathognomonic for insulin resistance, not malignancy. ### Pathophysiology of Insulin-Resistant AN 1. **Hyperinsulinemia** drives proliferation of epidermal and dermal fibroblasts via **insulin-like growth factor-1 (IGF-1) receptor signaling** 2. Results in: - Acanthosis (thickening of stratum spinosum) - Papillomatosis (finger-like projections) - Hyperkeratosis (excess keratin) - Hyperpigmentation (melanin deposition) 3. **Reversible** with: - Improved insulin sensitivity - Weight loss - Glycemic control ### Management Strategy for IRAAN ```mermaid flowchart TD A[Insulin-Resistant AN Diagnosed]:::outcome --> B[Primary: Optimize Metabolic Health]:::action B --> C[Glycemic Control]:::action B --> D[Weight Loss 5-10%]:::action B --> E[Insulin Sensitizers]:::action C --> F[Target HbA1c < 7%]:::outcome D --> G[Dietary modification + Exercise]:::outcome E --> H[Metformin, TZDs, GLP-1 RA]:::outcome I[Secondary: Symptomatic Relief]:::action I --> J[Topical keratolytics: Salicylic acid, urea]:::action I --> J --> K[Retinoids if severe]:::action L[Reassure: Benign, Reversible]:::action ``` **Clinical Pearl:** AN is a **marker of insulin resistance**, not a disease requiring dermatologic treatment alone. The skin findings improve as insulin sensitivity improves. ### Why Other Options Are Incorrect **Urgent malignancy screening (Option A):** - Not indicated in this patient - Red flags for MAAN are ABSENT: no weight loss, no rapid onset, no constitutional symptoms - Screening asymptomatic patients without clinical suspicion is not evidence-based - Would cause unnecessary anxiety and cost **Systemic retinoids (Option C):** - Reserved for severe, symptomatic IRAAN unresponsive to metabolic optimization - First-line is always metabolic management - Retinoids carry teratogenicity risk and require monitoring - This patient has not yet optimized insulin sensitivity **Oncology referral (Option D):** - Inappropriate without clinical or laboratory evidence of malignancy - No weight loss, no systemic symptoms, no rapid progression - Elevated insulin is reassuring AGAINST malignancy ### Evidence-Based Recommendations **High-Yield:** The **American Academy of Dermatology (AAD)** recommends: 1. **Metabolic workup:** glucose, insulin, lipids, assess for metabolic syndrome 2. **Lifestyle modification:** weight loss (5–10%), exercise, dietary changes 3. **Pharmacotherapy:** metformin (first-line), thiazolidinediones, GLP-1 receptor agonists 4. **Topical agents:** keratolytics (salicylic acid, urea 20–40%), retinoids if needed 5. **Reassurance:** AN is benign and reversible with metabolic improvement **Malignancy screening is indicated ONLY if:** - Rapid onset (< 1 year) - Weight loss (> 5% unintentional) - Age > 40 with no metabolic risk factors - Absence of obesity or DM - Systemic symptoms (fever, lymphadenopathy) This patient meets NONE of these criteria.